Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040025 | 0.86 | HDAC3 (0.50) | AKR1B1CYP2A6CA2GAAHSD17B10 | |
| SCHEMBL787824 | 0.82 | AKR1B1 (0.52) | AKR1B1CYP2A6CA2FBP1PFKFB4 | |
| SCHEMBL2088019 | 0.82 | CA2 (0.65) | AKR1B1CYP2A6CA2 | |
| SCHEMBL8231606 | 0.81 | FBP1 (0.53) | AKR1B1CYP2A6CA2FBP1PFKFB4 | |
| SCHEMBL3483777 | 0.79 | FBP1 (0.60) | AKR1B1CYP2A6CA2FBP1PFKFB4 | |
| SCHEMBL3680756 | 0.79 | CA2 (0.47) | CA2F10 | |
| SCHEMBL329450 | 0.76 | CA2 (0.67) | AKR1B1CYP2A6CA2 | |
| Hydrochloric Acid SCHEMBL27538000 | 0.74 | CA2 (0.65) | AKR1B1CYP2A6CA2 | |
| SCHEMBL12404107 | 0.73 | SMN1; SMN2 (0.50) | CA2GAAACP1KMT2ACYP1A2 | |
| SCHEMBL9350086 | 0.73 | AKR1B1 (0.45) | AKR1B1CYP2A6CA2FBP1PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | claimed |
| US-7863289-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |
| EP-2097414-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | claimed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | claimed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | claimed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1919475-A1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | claimed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7863289-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | disclosed |
| EP-0894088-A4 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6034093-A | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0894088-A1 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | AKR1B1 3322/4885CYP2A6 4605/4885CA2 3958/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | AKR1B1 2415/4885CYP2A6 3157/4885CA2 881/4885 |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | HTR6, HTR5A, HTR1B | AKR1B1 1742/4885CYP2A6 77/4885CA2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.